SMARCB1 and schwannoma: In view of the genetic heterogeneity, it might be expected that the molecular signature including changes in DNA methylation and gene expression associated with alterations in signalling pathways varies comparing sporadic schwannomas and those of patients with either NF2-, LZTR1- or SMARCB1-related SWN.